卡培他滨同步放疗治疗晚期食管癌对患者生活质量的影响

目的 探讨卡培他滨同步放疗对晚期食管癌的治疗效果及对患者生活质量的影响.方法 回顾性分析105例晚期食管癌患者的临床资料,根据治疗方法 的不同分为单纯放疗组(n=42)和卡培他滨联合放疗组(n=63).比较两组患者的治疗效果、治疗后生活质量和不良反应发生率.结果 卡培他滨联合放疗组的治疗有效率(80.95%)高于单纯放疗组(61.90%)(P﹤0.05).两组患者治疗前CEA、CA19-9和CA125水平比较,差异均无统计学意义(P﹥0.05);治疗后,卡培他滨联合放疗组的上述指标低于单纯放疗组,差异均有统计学意义(P﹤0.05).治疗后,卡培他滨联合放疗组的躯体化、焦虑、抑郁和敌对得分低于单纯放疗组(P﹤0.001),两组患者的人际关系敏感、强迫症状、恐怖、偏执和精神病性得分差异无统计学意义(P﹥0.05);两组患者恶心、呕吐、肝肾功能受损和骨髓抑制并发症总发生率比较,差异无统计学意义(P﹥0.05).结论 卡培他滨联合同步放疗对晚期食管癌有较好的治疗效果,可明显改善患者的生活质量,值得应用于临床.

Effect of Capecitabine concurrent chemoradiotherapy on the quality of life of patients with advanced esophageal cancer

Objective To investigate the therapeutic effect of concurrent Capecitabine radiotherapy in the treatment of advanced esophageal cancer and the influence on the quality of life (QOL) of patients. Method A retrospective was performed to analyze the clinical data of 105 patients with advanced esophageal cancer who were stratified as simple ra-diotherapy group (n=42) and Capecitabine plus radiotherapy group (n=63), of which the efficacy, postoperative QOL and adverse reaction rates were compared. Result The response rate in combined therapy group (80.95%) was significantly higher than that of radiotherapy group (61.90%);The two groups of patients had similar levels of CEA, CA19-9, CA125 before treatment (P>0.05);while after treatment, these measures were significantly decreased compared with that of the radiotherapy group (P<0.05). Furthermore, Capecitabine combined with radiotherapy achieved lower scores in regard of somatization, anxiety, depression and psychoticism than radiotherapy alone (P<0.001), though the interpersonal sensitivi-ty, compulsion symptoms, phobia, paranoid and psychotic scores were similar between the two groups (P>0.05); and there was no significant difference between the two groups in respect of the incidence of nausea, vomiting, liver and kid-ney dysfunction and bone marrow suppression (P>0.05). Conclusion Capecitabine combined with radiotherapy is effec-tively applicable in the treatment of advanced esophageal cancer, and can significantly improve the QOL of patients in clinical settings.